Amicus Therapeutics Inc (NAS:FOLD)
$ 10.135 -0.285 (-2.74%) Market Cap: 3.00 Bil Enterprise Value: 3.24 Bil PE Ratio: 0 PB Ratio: 18.43 GF Score: 79/100

Q4 2018 Amicus Therapeutics Inc Earnings Call Transcript

Feb 28, 2019 / 01:30PM GMT
Release Date Price: $12.1 (-2.65%)
Operator

Good day, ladies and gentlemen and welcome to Amicus Therapeutics Full year 2018 Financial Results and Corporate Update Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the conference over to your host, Sara Pellegrino, Vice President of Investor Relation and Corporate Communication. You may begin.

Sara Pellegrino
Amicus Therapeutics, Inc. - Senior Director of IR

Thanks, Nicole. Good morning and thank you for joining our conference call to discuss Amicus Therapeutics' full year 2018 financial results and 2019 corporate highlights.

Speaking on today's call, we have John Crowley, Chairman and Chief Executive Officer; Bradley Campbell, President and Chief Operating Officer; and Daphne Quimi, Chief Financial Officer. Dr. Jay Barth, Chief Medical Officer, is also here and Dr. Hung Do, Chief Science Officer, and Jeff Castelli, Chief Portfolio Officer and Head of Gene Therapy are participating from Philadelphia and available to participate in the Q&A session.

On

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot